Endoscopic versus microscopic surgery for treatment of middle ear cholesteatoma: A systematic review and meta-analysis.

Published
December 29, 2020
Journal
American journal of otolaryngology
PICOID
07b97e9e
DOI
Citations
21
Keywords
Cholesteatoma, Endoscope, Microscope, Recurrence, Residual
Copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Patients/Population/Participants

patients with middle ear cholesteatoma

Intervention

endoscopic ear surgery (EES)

Comparison

microscopic ear surgery (MES)

Outcome

recurrence of or residual disease, graft intake success rate, audiological performance, operation time

Abstract

P
I
C
O

Endoscopic ear surgery (EES) is minimally invasive and increasingly used to treat middle ear disease. In this meta-analysis, we compared the efficacies of EES and microscopic ear surgery (MES) in patients with middle ear cholesteatoma. The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for studies that reported the comparative surgical outcomes of EES and MES in patients with middle ear cholesteatoma. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. All included studies involved ≥1 of the following outcomes: recurrence of or residual disease, graft intake success rate, audiological performance, and operation time. We calculated the pooled relative risk (RR) or weighted mean difference with 95% confidence intervals (CIs) by using STATA software. Thirteen studies were included in the quantitative meta-analysis. The pooled recurrence and residual rates of cholesteatoma were significantly lower in the EES group than in the MES group [RR: 0.51, 95%CI: 0.31-0.84, heterogeneity (I The pooled results showed that EES reduced the residual lesion rate and postoperative recurrence risk in patients with middle ear cholesteatoma. However, there was insufficient evidence to prove that EES was advantageous in graft intake success rate auditory performance, and operation time.

Similar article map

CEO: Hwi-yeol YunCOO: Jung-woo ChaeCTO: Sangkeun Jung
Location: 204, W6, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea
Tel: 042-821-7328E-mail: webmaster@lilac-co.kr
Copyright © 2024 by LiLac. All Rights Reserved.